Related Experiment Videos
Development of myasthenia gravis after interferon alpha therapy
I G Gurtubay1, G Morales, O Aréchaga
1Clinical Neurophysiological Department, Virgen del Camino Hospital, Pamplona, Spain.
Electromyography and Clinical Neurophysiology
|April 20, 1999
Summary
Interferon alpha treatment can trigger myasthenia gravis (MG) or unmask a subclinical condition. This autoimmune response involves autoantibodies against acetylcholine receptors, potentially linked to cytokine release.
Area of Science:
- Neuroimmunology
- Oncology
- Hepatology
Background:
- Interferon (IFN) alpha is a therapeutic agent for malignant diseases and chronic viral hepatitis.
- Reports indicate IFN alpha can induce autoantibodies and autoimmune diseases or worsen existing conditions.
Observation:
- A case study details a patient developing myasthenia gravis (MG) after six weeks of IFN alpha treatment.
- Symptoms included ptosis, diplopia, and muscle weakness, with positive edrophonium chloride test, elevated anti-acetylcholine receptor (AChR) antibodies, and abnormal electromyography findings.
Findings:
- The patient was diagnosed with MG and initially responded to pyridostigmine, immunoglobulines, and prednisone.
- A subsequent myasthenic crisis with respiratory failure and high anti-AChR antibody titers occurred six months later.
Implications:
- IFN alpha may induce MG or reveal pre-existing subclinical MG.
- Autoimmune pathways, including cytokine release and autoantibody production against postsynaptic structures, are implicated in MG pathogenesis.
- Understanding these mechanisms is crucial for managing patients undergoing IFN alpha therapy.